Condition (MeSH)
Hepatorenal Syndrome
ClinicalTrials.gov lists 48 trials for Hepatorenal Syndrome or a narrower condition beneath it. Mallinckrodt has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
48 of the 48 trials are tagged with Hepatorenal Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Hepatorenal Syndrome trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 4 |
| 2020 | 2 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hepatorenal Syndrome trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 5 |
| Phase 3 | 6 |
| Phase 4 | 3 |
| Not applicable | 12 |
| Observational | 11 |
How many Hepatorenal Syndrome trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Completed | 24 |
| Suspended | 2 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hepatorenal Syndrome trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Mallinckrodt | 3 |
| Cumberland Pharmaceuticals | 1 |
| La Jolla Pharmaceutical Company | 1 |
| Lahore General Hospital | 1 |
Which drugs are being tested for Hepatorenal Syndrome? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Angiotensin II | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Terlipressinum | 11 |
| LAR Octreotide | 3 |
| Midodrine 2.5 mg tab | 2 |
| ALBUMIN | 2 |
| Terlipressin and albumin | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hepatorenal Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Respiratory failure | 25 | 2 |
| Chronic hepatic failure | 22 | 1 |
| Hepatic failure | 21 | 1 |
| Multiple Organ Dysfunction Syndrome | 18 | 1 |
| Chronic Hepatic Failure | 17 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hepatorenal Syndrome? (94)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. | Alimentary pharmacology & therapeutics | 2025 | Yes |
| Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. | Liver international : official journal of the International Association for the Study of the Liver | 2025 | Yes |
| Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome. | The Cochrane database of systematic reviews | 2024 | Yes |
| Allopurinol Prevents Cirrhosis-Related Complications: A Quadruple Blind Placebo-Controlled Trial. | The American journal of medicine | 2024 | Yes |
| Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography. | Hepatology (Baltimore, Md.) | 2024 | Yes |
Showing 5 of 94 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.